Media Articles Related to Erythra-Derm (Erythromycin Topical)
Health Tip: Avoiding Acne Triggers
Source: MedicineNet Acne Specialty [2014.03.18]
Title: Health Tip: Avoiding Acne Triggers
Category: Health News
Created: 3/18/2014 7:35:00 AM
Last Editorial Review: 3/18/2014 12:00:00 AM
Health Tip: Taming Acne
Source: MedicineNet Acne Specialty [2014.01.10]
Title: Health Tip: Taming Acne
Category: Health News
Created: 1/10/2014 7:35:00 AM
Last Editorial Review: 1/10/2014 12:00:00 AM
Clear Skin Pictures Slideshow: Helping Your Teen With Acne
Source: MedicineNet Boils Specialty [2013.11.07]
Title: Clear Skin Pictures Slideshow: Helping Your Teen With Acne
Created: 1/20/2010 3:54:00 PM
Last Editorial Review: 11/7/2013 12:00:00 AM
Source: MedicineNet Boils Specialty [2013.08.13]
Title: Acne (Pimples)
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 8/13/2013 12:00:00 AM
Pediatricians Endorse New Acne Treatment Guidelines
Source: MedicineNet isotretinoin Specialty [2013.05.06]
Title: Pediatricians Endorse New Acne Treatment Guidelines
Category: Health News
Created: 5/6/2013 10:35:00 AM
Last Editorial Review: 5/6/2013 12:00:00 AM
Published Studies Related to Erythra-Derm (Erythromycin Topical)
A comparison between the effectiveness of erythromycin, single-dose clarithromycin and topical fusidic acid in the treatment of erythrasma. [2011.09.18]
Abstract Although erythrasma is a superficial skin infection, there is no consensus on the treatment model of erythrasma... Conclusion: Topical fusidic acid proved to be the most effective treatment; however, clarithromycin therapy may be an alternative regimen in the treatment of erythrasma because of its efficiency and better patient's compliance.
Topical nadifloxacin 1% cream vs. topical erythromycin 4% gel in the treatment of mild to moderate acne. [2010.12]
Topical antibiotics are the mainstay of therapy in mild to moderate inflammatory acne... We conclude that when topically applied, both nadifloxacin 1% cream and erythromycin 4% gel are equally effective and safe treatments for mild to moderate facial acne.
Oral amoxicillin vs. oral erythromycin in the treatment of pyoderma in Bamako, Mali: an open randomized trial. [2007.10]
BACKGROUND: Pyoderma (bacterial superficial skin infection) is an extremely common disorder in tropical developing countries. In these settings, Streptococcus pyogenes is considered to be the main etiological agent. Apart from epidemics of poststreptococcal glomerulonephritis where mass treatment with intramuscular benzathine-penicillin is recommended, no recommendation exists for the treatment of pyoderma in this setting. The aim of this study was to evaluate the efficacy of oral amoxicillin in the treatment of pyoderma in Mali, by comparison with oral erythromycin... CONCLUSIONS: Amoxicillin was as efficacious as erythromycin in the treatment of severe pyoderma in Mali. Owing to its efficacy, added to high availability and low cost, this compound should be considered a first-line treatment of this disorder in this country, and perhaps in other countries where this condition presents in a similar way.
A randomized, double-blind, multicenter, parallel group study to compare relative efficacies of the topical gels 3% erythromycin/5% benzoyl peroxide and 0.025% tretinoin/erythromycin 4% in the treatment of moderate acne vulgaris of the face. [2003.01]
BACKGROUND: Combination treatments for acne vulgaris, such as Benzamycin (3% erythromycin/5% benzoyl peroxide) and Stievamycin (0.025% tretinoin/erythromycin 4%), reduce bacterial growth, which contributes to the inflammatory lesions typical of adolescent acne, and also decrease the epidermal cell compaction which may form the characteristic noninflammatory comedone. Both agents contain erythromycin to reduce the growth of Propionibacterium acnes in skin. Benzoyl peroxide has antibiotic activity as well as anticomedogenic properties. Tretinoin may increase the turnover of epidermal cells and loosen the cells compacted to form comedones. A combination preparation containing the two antibiotics may reduce the development of resistance; the combination preparation containing tretinoin and erythromycin will have an antibiotic effect as well as acting on differentiation... CONCLUSION: In moderate acne vulgaris, 3% erythromycin/5% benzoyl peroxide may provide a greater beneficial effect than 0.025% tretinoin/erythromycin 4%.
A randomized, parallel, vehicle-controlled comparison of two erythromycin/benzoyl peroxide preparations for acne vulgaris. [2002.05]
BACKGROUND: Topical erythromycin/benzoyl peroxide (EBP), marketed for acne treatment, must be compounded by a pharmacist and requires subsequent refrigeration, warranting the development of alternate formulations. OBJECTIVE: This trial compared the efficacy and tolerability of a single-use EBP combination package (EBP Pak) with those of its matching vehicle control (VC Pak) and the original, reconstituted formulation packaged in a jar (EBP Jar). The matching VC for the original formulation (VC Jar) was used to achieve study blinding... CONCLUSIONS: Results of this 8-week trial demonstrate that the single-use combination package of EBP is well tolerated, effective, and comparable to the original formulation for the treatment of acne vulgaris in this selected patient population.
Clinical Trials Related to Erythra-Derm (Erythromycin Topical)
The Effect of Concomitant Administration of Erythromycin and Diltiazem on CYP3A Activity in Healthy Volunteers [Completed]
We, the researchers at the Indiana University School of Medicine, are doing this study to
better understand how the effects of certain medications are altered when taken
simultaneously, or in combination with each other. We will also look at how each volunteer's
genes (DNA) may affect the way these medications are metabolized.
We will test the hypothesis that the extent of drug-drug interaction caused by the
combination of erythromycin and diltiazem is not predictable from the extent of interaction
produced by each inhibitor alone. Specifically we will test the hypothesis that the
combination of erythromycin and diltiazem will cause a greater decrease in midazolam
intravenous and oral clearance than the sum of the decreases caused by each inhibitor alone.
Comparison of Two Macrolides, Azithromycin and Erythromycin, for Symptomatic Treatment of Gastroparesis [Recruiting]
Erythromycin is effectively used in the treatment of Gastroparesis (GP) patients. In
susceptible patients however, it has been associated with sudden cardiac death due to
prolongation of QT intervals and subsequent cardiac risks through its interaction some other
drugs. Azithromycin (AZI) is a macrolide antibiotic but does not have the mentioned druf
interactions , has fewer gastrointestinal side effects, and fewer risks of QT prolongation
and cardiac arrhythmias. Consequently, AZI avoids drawbacks of dosing with erythromycin and
may be preferred as a prokinetic agent in patients on other concomitant medications.
We hope to demonstrate the effectiveness of Azithromycin (AZI) as compared to Erythromycin
in the treatment of Gastroparesis (GP), and later, form the framework for larger
randomized-controlled parallel studies to investigate use of AZI for treatment of GP.
Our novel hypothesis is to determine whether AZI can be used to treat GP.
Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin [Recruiting]
Dowling Meara type of epidermolysis bullosa simplex (EBS-DM) is a rare genodermatosis due to
keratin 5 and 14 mutation, characterized by skin fragility and spontaneous or post traumatic
blisters. Neonatal period and infancy are critical since this autonomic dominant affection
usually improves with age. Cyclins seem to be efficient in some cases of EBS but are
prohibited in children younger than 8 years old. Erythromycin can be a good alternative in
this population due to its antibacterial and anti-inflammatory potential.
The aim of this study is the evaluation of the efficiency of oral erythromycin to decrease
the number of cutaneous blisters in severe EBS-DM patients from 6 months to 8 years old
after 3 months of treatment.
Primary end point is the number of patients with decrease of blisters' number of at least
20% after 3 months of treatment by oral erythromycin.
It is a preliminary study on 8 patients. Treatment is oral erythromycin twice a day during 3
months. Follow up for each patient is 5 months. The duration of the study is 1 year.
A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function [Recruiting]
The purpose of this study is to evaluate the pharmacokinetics and pharmacodynamics of
rivaroxaban when administered with erythromycin to study participants with mild or moderate
renal impairment compared to the pharmacokinetics and pharmacodynamics of rivaroxaban
administered to study participants with normal renal function.
Methylnaltrexone vs Erythromycin for Facilitating Gastric Emptying Time in Critically Ill Patients [Recruiting]
42 patients admitted in ICU with intolerance to enteral feeding (GRV more than 250 ml) are
recruited. All patients enter a primary acetaminophen absorption test study as baseline.
Serum levels of acetaminophen will be measured by florescence polarization method at
15,30,45,60,90,120,180,240,480 minutes after enteral administration of 975 mg acetaminophen.
Then the patients will be randomized to methylnaltrexone or erythromycin group. Another
acetaminophen absorption test with the same schedule will be done after the last dose of
each drug. The area under the curve for acetaminophen blood level will be used to compare the
effect of two studied drugs on gastric emptying time.